Search results for "Renal cortex"

showing 10 items of 172 documents

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Roflumilast for asthma: Weighing the evidence

2015

CyclopropanesPulmonary and Respiratory Medicinebusiness.industryAdrenal cortex hormonesBiochemistry (medical)AminopyridinesPharmacologyPlacebomedicine.diseaseAsthmaAdrenal Cortex HormonesAdministration InhalationBenzamidesHumansMedicinePharmacology (medical)Phosphodiesterase 4 InhibitorsbusinessRoflumilastAsthmamedicine.drugAminopyridinesPulmonary Pharmacology & Therapeutics
researchProduct

Anti-inflammatory medications for the treatment of pediatric obstructive sleep apnea

2020

CyclopropanesPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classAnti-Inflammatory AgentsAdministration OralAcetatesSulfidesAnti-inflammatorylaw.inventionRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansChildAdministration IntranasalMontelukastSleep Apnea Obstructivebusiness.industryInfantmedicine.diseaseObstructive sleep apneaTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthQuinolinesLeukotriene Antagonistsbusinessmedicine.drugPaediatric Respiratory Reviews
researchProduct

Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.

2006

The widespread use of inhaled corticosteroids (ICS) for the treatment of persistent asthma, although highly effective, may be associated with both systemic and local side effects. Systemic side effects of ICS have been extensively studied. In contrast, relatively few studies have been performed to specifically evaluate local side effects of ICS. These local side effects--including oropharyngeal candidiasis, dysphonia, pharyngitis, and cough--are generally viewed as minor complications of therapy. However, they can be clinically significant, affect patient quality of life, hinder compliance with therapy, and mask symptoms of more serious disease. Local side effects result from deposition of …

DrugAdultmedicine.medical_specialtyAllergymedicine.drug_classmedia_common.quotation_subjectImmunologyOropharynxCiclesonideOropharyngeal Candidiasischemistry.chemical_compoundAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumansIntensive care medicineChildmedia_commonAsthmaVoice DisordersInhalationbusiness.industryCandidiasisPharyngitismedicine.diseasePharyngitisAsthmachemistryCoughAnesthesiaCorticosteroidmedicine.symptombusinessAllergy
researchProduct

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Ca…

2018

The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages …

DrugGenetics and Molecular Biology (all)Malemedicine.medical_specialtyExacerbationArticle SubjectImmunology and Microbiology (all)media_common.quotation_subjectlcsh:MedicineClinical manifestationBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsmedicineHumansDrug InteractionsStage (cooking)media_commonRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)General Immunology and MicrobiologyBone Density Conservation AgentsDiphosphonatesbusiness.industrylcsh:ROsteonecrosisSoft tissueCancer030206 dentistryGeneral Medicinemedicine.diseaseZoledronic acidBiochemistry Genetics and Molecular Biology (all) Immunology and Microbiology (all)Italy030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleTaxoidsbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugResearch ArticleBioMed Research International
researchProduct

Novel inulin-based mucoadhesive micelles loaded with corticosteroids as potential transcorneal permeation enhancers

2017

In this work a new copolymer of inulin (INU) derivatized with ethylendiamine (EDA) and retinoic acid (RA), named INU-EDA-RA, was synthetized, characterized and employed to produce micelles as carriers for topical administration of corticosteroids for the potential treatment of diseases of posterior eye segment. Spectroscopic analysis confirmed a molar derivatization degree of 11.30 and 4.30% in EDA and RA, respectively. INU-EDA-RA micelles are capable of strong mucoadhesive interactions which result time-independent and stable over time but concentration depending. Moreover micelles are able to encapsulate efficiently from 3 to 13% (w/w) of lipophilic drugs, as dexamethasone, triamcinolone …

DrugTriamcinolone acetonideTranscorneal enhancerCell SurvivalSwineAdministration Topicalmedia_common.quotation_subjectTranswellPharmaceutical ScienceMucoadhesionRetinal Pigment Epithelium02 engineering and technologyOcular disease030226 pharmacology & pharmacyMicellePermeabilityCorneaMice03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesPolymeric micelleRetinoic acidCell AdhesionMucoadhesionmedicineCorticosteroidAnimalsHumansDissolution testingOcular topical administrationMicellesmedia_commonDrug CarriersChromatographyDose-Response Relationship DrugChemistryInulinGeneral Medicine021001 nanoscience & nanotechnologyPermeability (electromagnetism)Cattle0210 nano-technologyDrug carrierDrug metabolismBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

In situ delivery of corticosteroids for treatment of oral diseases.

2017

In many mucocutaneous disorders, corticosteroids therapy is currently central. Systemic therapy is restricted to severe disorders whereas topical applications are considered as the first-line treatment. The oral cavity environment, the medication form and other factors related to the delivery method are key factors for the therapy efficiency and effectiveness. Current marketed medications are not able to avoid wrong drug exposure and scarce patients’ compliance. Innovative in situ delivery systems are able to prolong the drug retention time on the mucosa and to avoid the drawbacks of conventional formulations. This review is intended to give a general overview of oral mucocutaneous patholo…

Drugcorticosteroidmedicine.medical_specialtymedia_common.quotation_subjectMucocutaneous zonePharmaceutical ScienceOral cavitySystemic therapy03 medical and health sciences0302 clinical medicineDrug Delivery Systemsin situ deliveryAdrenal Cortex HormonesMedicineHumansoral diseaseIntensive care medicinemedia_commonWrong drugbusiness.industryMouth Mucosa030206 dentistrySurgeryKey factorsSettore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisbusinessMouth DiseasesRetention timeTherapeutic delivery
researchProduct

Safety of the current drug treatments for vitiligo

2020

Introduction: Vitiligo is an acquired depigmenting skin disorder adversely affecting the patient's quality of life. Despite the presence of several treatment modalities, ranging from medical to physical to surgical options, none is curative. Each modality has its own drawbacks and side effects. Thus, the treatment modality needs to be tailored for each individual patient taking into consideration the disease characteristics and also its efficacy and safety to obtain a favorable risk-benefit ratio.Areas covered: This review highlights the different treatment modalities utilized in vitiligo up until 4 November 2019 along with their adverse effects and contraindications, if any.Expert opinion:…

Drugmedicine.medical_specialtymedia_common.quotation_subjectVitiligoVitiligo030204 cardiovascular system & hematologyAdministration Cutaneous03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Adrenal Cortex HormonesmedicineHumansEffective treatmentPharmacology (medical)Intensive care medicineAdverse effectmedia_commonBiological ProductsModality (human–computer interaction)business.industryGeneral Medicinemedicine.diseaseTreatment modality030220 oncology & carcinogenesisQuality of LifeDisease characteristicsDermatologic AgentsbusinessExpert Opinion on Drug Safety
researchProduct

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management
researchProduct